Latest
Pharma is investing heavily in AI-driven CRM and 'next-best-action' tools, but engagement quality hasn’t kept pace. This is a capability gap, not a technology gap.
Read article: Data-rich, insight-poor: why human judgement drives pharma's AI payoff
Together with BluePath Health, we recently brought together a small group of cross-sector health leaders in New York for an intimate dinner salon to tackle a shared challenge: why adoption in healthcare still moves too slowly, even when innovation is strong. The conversation centered on what decision-ready evidence really looks like, and how tools like clinical simulation and data sandboxes can help teams learn faster, reduce risk earlier, and move from evidence to action.
Read article: From evidence to action: what it takes to speed adoption in health care
Germany’s pioneering 'apps on prescription' model offers the most structured entry point into the European digital health and medtech market. With access to 73 million insured lives, the potential for scale is unmatched, but the barrier to entry is high. This guide breaks down the essential steps for securing DiGA reimbursement in Germany, from navigating the BfArM Fast-Track and building the right clinical evidence, to preparing for the major regulatory shifts arriving in 2026.
The Prova Health Pulse is our latest roundup of what we’ve been working on, and the best of what’s caught our eye across the world of health innovation. In this issue: addressing adoption barriers for new drugs, evaluating LLMs in healthcare, building the future of UK health data and more.
Even the most groundbreaking drugs rarely reach their full commercial potential because of adoption friction: the structural and logistical realities that slow or limit their integration into health systems. Achieving a successful pharma product launch is difficult; 1 in 2 new drugs fail to meet launch forecasts. The emergence of the first treatments for MASH serves as a key case study, illustrating how diagnostic gaps, workforce shortages, and fragmented care create friction that leads to delayed or limited uptake. To maximise commercial success and ensure new products perform on launch expectations, companies must identify, characterise, and overcome the specific systemic barriers in key markets.
Large Language Models (LLMs) are reshaping healthcare, but how do we ensure they work safely and reliably for clinicians? Traditional trials are too slow and costly for digital health's rapid cycles, while early testing doesn't prove clinical validity. Clinical simulation offers a promising way forward, putting these tools in clinicians' hands, in realistic scenarios, to test their real-world performance. We believe this methodology should become a core part of how we validate LLM-based technologies before they reach clinical settings.
Read article: Rapid and safe evaluations of LLMs: how clinical simulation closes the evidence gap
Discover how AI workforce solutions transform revenue cycle management. Learn 3 key metrics to measure ROI and boost healthcare financial performance.
Prova Health’s Capability Building work is central to our mission of improving health for all by supporting innovation. We sat down with Dr Des Conroy, our recently-appointed Head of Capability Building, to learn more about his and Prova’s journey to this point, and what’s to come.
Read article: Capability Building for healthcare and life sciences
US healthcare reimbursement is complex. Understanding the ecosystem is critical to navigate routes to market for digital health solutions.
Read article: Navigating US healthcare reimbursement: taking digital health solutions to market
Trust is a core factor influencing the adoption of AI in healthcare. Vital to fostering this trust is robust evidence.
A new white paper in development by Prova Health aims to clarify the evidence required for AI solutions in healthcare.
Clinicians expect sufficient regulation and robust validation of AI-based medical devices. There remains a need for clear, AI-specific...
Read article: Improving the adoption of AI: clinician perspectives
Remote monitoring and wearables are promising solutions, which need evidence showing value for patients, clinicians and healthcare systems.
Read article: From data to insights: evidence for remote monitoring and wearables
Optimising reimbursement models for digital health solutions is critical for improving the quality of solutions on the market, and boosting
Read article: Evidence, reimbursement and routes to market in digital health
Generating evidence for digital health solutions is a challenge. Novel approaches such as simulation, RWE and platform trials can help.
Prova Health conducted an evaluation of Accurx's Self-Book product. This article shares some of the lessons we learned in the process.
Read article: Demonstrating the value of digital health solutions with real-world evidence
A new white paper by Roche Information Solutions and Prova Health offers solutions on how to improve evidence standards and reimbursement...
Read article: Reaching a global consensus on evidence for digital health
Most digital solutions lack evidence, but more than ever innovators must show value to patients, clinicians, health systems and investors.
Read article: The rising demand for evidence in digital health
